Abstract
Inclusion body myositis (IBM) is a slowly progressive myopathy with unique clinical and pathological features. So far, there are several case reports of patients with IBM and HTLV-I infection. However, there is no study that investigated clinical features of IBM associated with HTLV-I infection. We investigated the clinical differences between the IBM patients with and without anti-HTLV-I antibodies. In 402 patients enrolled into the study, 250 patients fulfilled the ENMC2011 criteria for diagnoses of IBM. Among them, 12, 171, and 67 patients were positive, negative, and unexamined for anti-HTLV-I antibodies, respectively. The patients with the antibodies significantly started with difficulty in ambulation, and tended to exhibit a male predominance, preserved respiratory function, and effectiveness of steroid therapy. The IBM patients with anti-HTLV-I antibodies showed similar clinical features as those without the antibodies, except a frequent onset of difficulty in ambulation, at the instant of diagnoses. However, longitudinal analyses would be necessary to understand the effect of HTLV-I infection on the clinical course of IBM.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
